EQ - Equillium, Inc.

0.3905
-0.009   -2.177%

Share volume: 47,020
Last Updated: 05-09-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.09%

PREVIOUS CLOSE
CHG
CHG%
$0.40
-0.01
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
46%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 60%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.36%
1 Month
-19.70%
3 Months
-48.95%
6 Months
-48.95%
1 Year
-48.95%
2 Year
-48.95%
Key data
Stock price
$0.39
P/E Ratio 
0.00
DAY RANGE
$0.37 - $0.40
EPS 
-$0.16
52 WEEK RANGE
$0.34 - $0.87
52 WEEK CHANGE
-$48.95
MARKET CAP 
26.509 M
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$84,694
AVERAGE 30 VOLUME 
$85,000
Company detail
CEO: Bruce D. Steel
Region: US
Website: equilliumbio.com
Employees: 40
IPO year: 2018
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Equillium, Inc. develops and sells products to treat severe autoimmune and inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6.

Recent news
loading